Lifordi Immunotherapeutics Reports Promising Preclinical Data for Autoimmune Treatment LFD-200
Lifordi Immunotherapeutics will present new preclinical data showing its antibody drug conjugate LFD-200 delivers glucocorticoids directly to immune cells with sustained anti-inflammatory effects and no systemic toxicity, potentially offering a safer treatment option for autoimmune diseases.
Lifordi Immunotherapeutics, Inc. will present additional preclinical data on its lead candidate LFD-200, an antibody drug conjugate delivering a potent glucocorticoid directly to immune cells, at the upcoming American College of Rheumatology Convergence 2025 meeting. The new findings from multiple in vitro and in vivo studies in non-human primates demonstrate that LFD-200 achieves targeted and sustained delivery of its glucocorticoid payload to immune cells without concurrent safety signals, potentially providing the efficacy of steroids without systemic toxicity.
The research shows LFD-200 selectively delivers glucocorticoid to immune tissues and results in inhibition of ex vivo induced inflammatory cytokines with no observed systemic toxicity at clinically relevant doses. This targeted approach represents a significant advancement in autoimmune treatment, as traditional glucocorticoid therapies often cause widespread side effects throughout the body due to their non-selective nature. The sustained anti-inflammatory effects observed in the studies suggest LFD-200 could provide longer-lasting relief with less frequent dosing compared to current treatments.
The data will be presented during the Rheumatoid Arthritis – Treatment Poster I session on Sunday, October 26, 2025, under the title "LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates." This presentation comes as LFD-200 advances through clinical development, currently in a Phase 1 clinical trial after demonstrating efficacy in multiple preclinical disease models.
Lifordi's approach leverages the success of antibody drug conjugates, traditionally used in oncology, to develop treatments for autoimmune and inflammatory disorders. The company targets myeloid and lymphoid cells using a highly internalized cell surface membrane protein called VISTA. This technology platform has broader applications beyond glucocorticoids, having been applied to other diverse payloads including small molecules, antisense oligonucleotides, and siRNA. For more information about the company's research and development programs, visit https://www.lifordi.com.
The implications of this research are substantial for the approximately 50 million Americans living with autoimmune diseases who often face difficult trade-offs between treatment efficacy and side effects. Current glucocorticoid treatments, while effective at controlling inflammation, frequently cause systemic side effects including weight gain, mood changes, osteoporosis, and increased infection risk. LFD-200's targeted delivery approach could potentially revolutionize autoimmune treatment by maintaining therapeutic benefits while minimizing these debilitating side effects, offering patients improved quality of life and better long-term treatment adherence.